TY - JOUR
T1 - A targeted genetic association study of epithelial ovarian cancer susceptibility
AU - Earp, Madalene
AU - Winham, Stacey J.
AU - Larson, Nicholas
AU - Permuth, Jennifer B.
AU - Sicotte, Hugues
AU - Chien, Jeremy
AU - Anton-Culver, Hoda
AU - Bandera, Elisa V.
AU - Berchuck, Andrew
AU - Cook, Linda S.
AU - Cramer, Daniel
AU - Doherty, Jennifer A.
AU - Goodman, Marc T.
AU - Levine, Douglas A.
AU - Monteiro, Alvaro N.A.
AU - Ness, Roberta B.
AU - Pearce, Celeste L.
AU - Rossing, Mary Anne
AU - Tworoger, Shelley S.
AU - Wentzensen, Nicolas
AU - Bisogna, Maria
AU - Brinton, Louise
AU - Brooks-Wilson, Angela
AU - Carney, Michael E.
AU - Cunningham, Julie M.
AU - Edwards, Robert P.
AU - Fogarty, Zachary C.
AU - Iversen, Edwin S.
AU - Kraft, Peter
AU - Larson, Melissa C.
AU - Le, Nhu D.
AU - Lin, Hui Yi
AU - Lissowska, Jolanta
AU - Modugno, Francesmary
AU - Moysich, Kirsten B.
AU - Olson, Sara H.
AU - Pike, Malcolm C.
AU - Poole, Elizabeth M.
AU - Rider, David N.
AU - Terry, Kathryn L.
AU - Thompson, Pamela J.
AU - Van Den Berg, David
AU - Vierkant, Robert A.
AU - Vitonis, Allison F.
AU - Wilkens, Lynne R.
AU - Wu, Anna H.
AU - Yang, Hannah P.
AU - Ziogas, Argyrios
AU - Phelan, Catherine M.
AU - Schildkraut, Joellen M.
AU - Chen, Yian Ann
AU - Sellers, Thomas A.
AU - Fridley, Brooke L.
AU - Goode, Ellen L.
N1 - Funding Information:
Funding support for the Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) was provided through the National Cancer Institute's Cancer Post-GWAS Initiative, Genetic Associations and Mechanisms in Oncology (GAME-ON) (U19-CA148112). In addition, we acknowledge the following: DOV: National Institutes of Health R01-CA112523 and R01-CA87538; HAW: National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); HOP: DOD DAMD17-02-1-0669 and NCI K07-CA080668, R01-CA95023, P50-CA159981; NIH/National Center for Research Resources/General Clinical Research Center grant M01-RR000056; MAY: National Institutes of Health (R01-CA122443, P30-CA15083-41, P50-CA136393); NCO: National Institutes of Health (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666); NEC: National Institutes of Health R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NHS: NIH (P01-CA87696 and R01-CA49449): NJO: National Cancer Institute (K07-CA095666, R01-CA83918, K22-CA138563, and P30-CA072720) and the Cancer Institute of New Jersey; NCI CCSG award (P30-CA008748); OVA: This work was supported by Canadian Institutes of Health Research grant (MOP-86727); LEK is supported by a Canadian Institutes of Health Research New Investigator award (MSH-87734); POL: Intramural Research Program of the National Cancer Institute; UCI: R01-CA058860, R01-CA092044, US Public Health Service PSA-042205, and the Lon V Smith Foundation grant LVS-39420; USC: P01-CA17054, P30-CA14089, R01-CA61132, N01-PC67010, R03-CA113148, R03-CA115195, N01-CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200). CMP is supported by National Institutes of Health R01-CA-149429.
PY - 2016
Y1 - 2016
N2 - Background: Genome-wide association studies have identified several common susceptibility alleles for epithelial ovarian cancer (EOC). To further understand EOC susceptibility, we examined previously ungenotyped candidate variants, including uncommon variants and those residing within known susceptibility loci. Results: At nine of eleven previously published EOC susceptibility regions (2q31, 3q25, 5p15, 8q21, 8q24, 10p12, 17q12, 17q21.31, and 19p13), novel variants were identified that were more strongly associated with risk than previously reported variants. Beyond known susceptibility regions, no variants were found to be associated with EOC risk at genome-wide statistical significance (p <5x10-8), nor were any significant after Bonferroni correction for 17,000 variants (p< 3x10-6). Methods: A customized genotyping array was used to assess over 17,000 variants in coding, non-coding, regulatory, and known susceptibility regions in 4,973 EOC cases and 5,640 controls from 13 independent studies. Susceptibility for EOC overall and for select histotypes was evaluated using logistic regression adjusted for age, study site, and population substructure. Conclusion: Given the novel variants identified within the 2q31, 3q25, 5p15, 8q21, 8q24, 10p12, 17q12, 17q21.31, and 19p13 regions, larger follow-up genotyping studies, using imputation where necessary, are needed for fine-mapping and confirmation of low frequency variants that fall below statistical significance.
AB - Background: Genome-wide association studies have identified several common susceptibility alleles for epithelial ovarian cancer (EOC). To further understand EOC susceptibility, we examined previously ungenotyped candidate variants, including uncommon variants and those residing within known susceptibility loci. Results: At nine of eleven previously published EOC susceptibility regions (2q31, 3q25, 5p15, 8q21, 8q24, 10p12, 17q12, 17q21.31, and 19p13), novel variants were identified that were more strongly associated with risk than previously reported variants. Beyond known susceptibility regions, no variants were found to be associated with EOC risk at genome-wide statistical significance (p <5x10-8), nor were any significant after Bonferroni correction for 17,000 variants (p< 3x10-6). Methods: A customized genotyping array was used to assess over 17,000 variants in coding, non-coding, regulatory, and known susceptibility regions in 4,973 EOC cases and 5,640 controls from 13 independent studies. Susceptibility for EOC overall and for select histotypes was evaluated using logistic regression adjusted for age, study site, and population substructure. Conclusion: Given the novel variants identified within the 2q31, 3q25, 5p15, 8q21, 8q24, 10p12, 17q12, 17q21.31, and 19p13 regions, larger follow-up genotyping studies, using imputation where necessary, are needed for fine-mapping and confirmation of low frequency variants that fall below statistical significance.
KW - Genetic association
KW - High-grade serous carcinoma
KW - NF-κB
KW - Ovarian cancer
KW - Susceptibility loci
UR - http://www.scopus.com/inward/record.url?scp=84958817754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958817754&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.7121
DO - 10.18632/oncotarget.7121
M3 - Article
C2 - 26848776
AN - SCOPUS:84958817754
SN - 1949-2553
VL - 7
SP - 7381
EP - 7389
JO - Oncotarget
JF - Oncotarget
IS - 7
ER -